Which Regener-Eyes will be marketed at American Academy of Ophthalmology?
Regener-Eyes is scheduled to appear in the exhibit hall at the American Academy of Ophthalmology’s Annual Meeting, which takes place November 3-6, 2023 in San Francisco.
But which Regener-Eyes will show up?
5. The eye drop with Dissociative Immunosuppressant Identity Disorder?
Is it immunosuppressive? (Says so in the White Paper about Regener-eyes (Eyeworld, July 2021.)
Is it NOT immunosuppressive? (Says so in the Regener-Eyes brochure.)
6. The eye drop with Dissociative Ingredient Identity Disorder?
Is it amniotic fluid? (Says so in various patent applications and, honestly, all over the internet.)
Is it NOT amniotic fluid? (Sales people said so to a journalist at a trade show earlier this year.)
Is it placental proteins? (Says so in the White Paper and on prominent eye doctors’ websites, like this one.)
Is it glycerin, water and d-MAPPS ™ (and if so, what’s that)? (Said so on DailyMed before we called them out, but only in the fake-out part of the drug listing.)
Is it glycerin, water and Tonicity Solution™ (and if so, what’s that)? (Ditto, after we called them out.)
Is it glycerin and water? (Used to say so on DailyMed, when you scrolled past the fake-out part and looked at the data tables where real ingredients live.)
Is it glycerin and sodium chloride and water? (Ditto, in the updated version several months later.)
Is your head spinning? Of course.
The real Regener-Eyes secret sauce: Confusion.
Raise your hand if you understand FDA rules about eye drops.
No one does.
So, most people (in this case, eye care professionals) trust what they are told.
Then along comes a company that is not trustworthy. And digs in - for the long haul.
Sadly, by the time the facts began to emerge through DEF’s 2022 exposé, too many people were too attached to their beliefs to be willing to consider facts. Thus, the farce continues and public FDA rebukes are being disregarded.
We have even heard that reputable ophthalmologists are suggesting to peers that the FDA itself condones industry selling eye drops with unspecified active ingredients so long as those ingredients are not included in the labeling. This is a patent absurdity and a gross misrepresentation of regulatory authorities’ clearly stated descriptions of Regenere-Eyes.
One thing remains very simple:
We patients deserve to know what’s in the bottle.
And no doctor should be asking us to put something in our eyes when they cannot tell us what it is.